Bladder Cancer Clinical Trials in Washington D.C., District of Columbia

8 studies are recruiting for bladder cancer in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

   This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Johns Hopkins Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   20 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07277413 on ClinicalTrials.gov

2. A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

   Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial me…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sibley Memorial Hospital ( Site 0849), Washington D.C., District of Columbia

   Locations

   94 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07419295 on ClinicalTrials.gov

3. Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

   This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Johns Hopkins University: Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05312671 on ClinicalTrials.gov

4. Renal Retention in High Grade Upper Tract Urothelial Cancer

   This trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer (UTUC), preferring to forego standard of care radical nephroureterectomy (RNU)…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Johns Hopkins University: Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05656235 on ClinicalTrials.gov

5. Blue Light Cystoscopy With Cysview® Registry

   Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   23 in total

   Run by

   Photocure

   See if you can join NCT02660645 on ClinicalTrials.gov

6. Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

   The purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy. Patients will be randomized to one of two groups: prostate capsule-sparing radical cystectomy…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05792722 on ClinicalTrials.gov

7. Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

   Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualizatio…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Johns Hopkins University

   See if you can join NCT06525571 on ClinicalTrials.gov

8. Gender Related Coping and Survivorship for Genitourinary Cancers

   This research is being done to learn more about coping and survivorship of women with bladder cancer, specifically regarding psychosocial distress and sexual dysfunction. This study is a non-therapeutic study and will randomize participants to a standard of care group and education group. Patients …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05649306 on ClinicalTrials.gov